Brilinta No Better Than Aspirin In Stroke Trial
This article was originally published in Scrip
Topline data from the SOCRATES trial of Brilinta (Brilique; ticagrelor) provided more ammunition for those pushing for AstraZeneca's CEO Pascal Soriot to have his pay linked to performance.
You may also be interested in...
Keeping Track: Kite’s Tecartus Is Third CAR-T With US FDA Approval; Submissions Round-Up
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Brilinta/Bydureon’s Measurable Outcomes Are Smooth Fit For Contracts
Three-year contracts between AstraZeneca and Harvard Pilgrim focus on reduced hospitalization for Brilinta, reaching HbA1c goals for Bydureon; choosing appropriate products and outcomes are key challenge for the new reimbursement approaches.